In a significant realignment within the healthcare sector’s financial leadership, Cardinal Health has announced the appointment of Anita Zielinski as its new Chief Accounting Officer (CAO). Zielinski, who currently serves as the interim CFO, chief accounting officer, and controller at Baxter International, will transition to her new role this November, marking the end of a brief but pivotal tenure at the medical technology giant.
The transition, confirmed by regulatory filings in early August, underscores a period of intense executive movement as both companies navigate complex market pressures and organizational restructuring.
Main Facts: A Strategic Transition
Anita Zielinski is set to join Cardinal Health on November 5, 2026, assuming the role of Chief Accounting Officer and succeeding current CAO Mary Scherer. Her departure from Baxter is scheduled for September 15, 2026.
The move represents a high-profile acquisition of talent for Cardinal Health. According to securities filings, the compensation package secured by Zielinski reflects her standing in the industry. Her offer includes a $750,000 cash sign-on bonus and an additional $1 million in restricted stock units (RSUs), which are slated to vest over a three-year period. This competitive package highlights the premium placed on experienced financial oversight in the highly regulated medical distribution and pharmaceutical sector.
Chronology: A Trajectory of Financial Leadership
To understand the significance of this move, one must examine Zielinski’s professional trajectory, which is defined by long-term commitment and high-stakes transitions.
The Foundation: Decades at Ernst & Young
Before her recent executive roles, Zielinski spent over two decades at the accounting powerhouse Ernst & Young (EY). This tenure provided her with the technical rigor and regulatory fluency required to navigate the complex financial landscapes of public corporations. Her 20-year career at EY served as the bedrock for her transition into corporate leadership.
The Seven-Year Tenure at Sysco
Following her time at EY, Zielinski transitioned to the corporate sector, spending seven years at Sysco. Her tenure there allowed her to manage complex supply chain accounting and large-scale operational financial reporting, preparing her for the challenges of the healthcare and medtech industries.
The Baxter Chapter: A Rapid Ascent
Zielinski joined Baxter in February 2025 as the company’s Chief Accounting Officer and Controller. Her arrival coincided with a period of profound turbulence for the company. By March 2025, following the departure of long-standing CFO Joel Grade, Zielinski was thrust into the role of interim CFO. In this capacity, she navigated a period marked by leadership turnover, the divestiture of major business units, and the aftermath of significant operational disruptions caused by environmental events.
Supporting Data: Compensation and Market Context
The financial terms of Zielinski’s move to Cardinal Health are illustrative of the current "war for talent" among C-suite executives in the Fortune 500.
The Compensation Breakdown
- Sign-on Bonus: $750,000 (Cash).
- Equity Incentives: $1 million in restricted share units (RSUs).
- Vesting Schedule: Three-year timeline, designed to ensure long-term retention and alignment with shareholder interests.
These figures are consistent with the market rates for executive-level financial officers overseeing the books of multi-billion-dollar entities. By incentivizing the move with a substantial equity stake, Cardinal Health is signaling its intent to rely on Zielinski’s expertise as it continues to optimize its own financial reporting and capital allocation strategies.
Official Responses and Organizational Implications
Both Baxter and Cardinal Health have framed these changes as part of their broader strategic goals. For Cardinal Health, the appointment is a move toward continuity and rigorous oversight. For Baxter, however, the departure of an interim CFO leaves a gap that the company must fill amidst a series of broader, ongoing organizational shifts.
Baxter’s Ongoing Transformation
Baxter has not yet announced a successor for the CFO position. This vacancy comes at a delicate time. As of July 2025, Baxter appointed a new CEO, a move intended to stabilize the company after a tumultuous period.
The company has been forced to grapple with several structural challenges:
- Manufacturing Resilience: The firm spent much of the previous year recovering from severe hurricane damage to a critical manufacturing plant, which necessitated extensive financial re-forecasting.
- Portfolio Optimization: Baxter has undergone a series of divestitures, most notably offloading its kidney care and biopharma solutions units. These moves were designed to sharpen the company’s focus on its core medical technology offerings but required the type of complex accounting expertise that Zielinski provided.
The View from Cardinal Health
Cardinal Health is positioned differently. As a distributor and service provider in the healthcare supply chain, their focus remains on maintaining absolute accuracy in accounting to support their thin-margin, high-volume business model. By bringing in Zielinski, Cardinal Health gains an executive who is battle-tested in corporate restructurings and has recent experience managing the financial complexities of a major manufacturing-based enterprise.
Implications: The Future of Healthcare Finance
The departure of an interim CFO is rarely a neutral event. It serves as a diagnostic indicator of the health and stability of the organization involved.
1. The Challenge of Interim Leadership
Interim roles, by their nature, create a bridge between eras. Zielinski’s role at Baxter was to hold the fort while the company searched for long-term solutions and navigated structural divestitures. Her move to Cardinal Health suggests that the transition at Baxter—or at least her specific role in it—has reached a level of maturity where she feels comfortable moving on to a permanent, executive-level position elsewhere.
2. Talent Scarcity in the C-Suite
The ease with which Zielinski moved from a high-stakes interim role to a permanent CAO position at a major company like Cardinal Health highlights the scarcity of high-level financial talent. CFOs and CAOs are currently expected to do much more than balance the books; they are expected to be strategic partners in M&A, supply chain risk management, and digital transformation.
3. Regulatory Pressures
As the SEC continues to tighten requirements for financial reporting and internal controls, companies are increasingly looking for leaders with deep experience in compliance—a skill set that Zielinski clearly honed during her 20 years at Ernst & Young. Her move is a defensive and offensive play for Cardinal Health, ensuring they have the leadership needed to stay ahead of regulatory curves.
4. Market Perception
Investors often view executive turnover with a mix of caution and optimism. While the departure of an interim CFO can cause short-term uncertainty, the hiring of an experienced executive like Zielinski by Cardinal Health is likely to be viewed as a positive sign of professional governance. Conversely, Baxter’s ability to successfully appoint a permanent CFO will be a key metric for shareholders in the coming quarters.
Conclusion: A New Chapter
As Anita Zielinski prepares to close her tenure at Baxter and begin her work at Cardinal Health, the industry is reminded of the fluidity of corporate leadership. The healthcare sector remains a complex environment, where financial strategy is inextricably linked to operational, regulatory, and environmental challenges.
For Zielinski, the move represents a return to a permanent, long-term strategic role after a period of intense crisis management. For the companies involved, it marks a pivot point. Baxter continues its effort to redefine itself post-divestiture, while Cardinal Health solidifies its accounting leadership to navigate the next phase of its growth.
As the industry observes these developments, the focus will shift to who Baxter selects to fill the void and how Zielinski’s presence at Cardinal Health influences their financial trajectory into 2026 and beyond. In the interconnected world of medical and pharmaceutical business, the appointment of a single officer can often be the catalyst for broader organizational shifts, underscoring that in the modern corporation, the person behind the ledger is as critical as the figures themselves.
